At a glance
ClinicalIndex Comparison RecordN/ACompleted· 8 enrolled
Drug / intervention
Intranasal Oxytocindrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label Trial of Oxytocin in Adolescents With Autism Spectrum Disorders
In Brief
A clinical study evaluating Intranasal Oxytocin for Autism Spectrum Disorders and 3 related conditions. Completed, enrolled 8 participants across 1 site.
Detailed Summary
This study is an 8-week open-label trial testing oxytocin nasal spray (Syntocinon) as a treatment for social impairment in adolescents with autism spectrum disorders (ASD). We hypothesize that oxytocin nasal spray will be safe, tolerable, and effective in improving the core symptoms of autism spectrum disorders in adolescents ages 11-17.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAutism Spectrum Disorders, Pervasive Developmental Disorders, ASD, PDD
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedAug 2013
Enrollment StartOct 2013
Primary CompletionFeb 2016
TodayJul 2026
First PostedAug 29, 2013
Enrollment StartOct 1, 2013
Primary CompletionFeb 22, 2016
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 12.8 years ago
Interventions
Intranasal Oxytocindrug